ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

J&J, Amgen Settle Lawsuit Over ESAs As FDA Prepares Another Label Change.

July 18, 2008

Hearing Probes CDC On Cancer Treatment For Working Poor In Screening Program

July 23, 1999

ODAC Finds Increase In Progression-Free Survival Unconvincing To Approve sNDA For Gemzar In Advanced Ovarian Cancer.

March 24, 2006

In Brief: Hopkins Wins SPORE in Gastointenstinal Cancers; Nurses Group Calls For Proposals

January 21, 1994

In Brief: Fox Chase Joins Temple Health System, Expands Outpatient and Surgical Services

July 6, 2012

Funding Opportunities (8-page issue).

April 25, 2003